AN UNUSUAL TYPE OF SOLID CARCINOMA OF SALIVARY GLANDS: A CLINICOPATHOLOGIC AND IMMUNOHISTOCHEMICAL STUDY

An unusual histologic type and low-grade malignancy of salivary gland (SG) carcinomas, namely solid carcinoma (SC), is reported. Histopathologic characteristics of 12 cases of the SC include (1) large solid nest structure, (2) isomorphic and blandness of the epithelial cells in cytoloogy, (3) squamous metaplasia and keratinization in different degrees. (4) infiltrative growth pattern. Immunohistochemical stainings reveal that the cells of the SCs are reacted positive with anti-cytokeratins 12 and 27, anti-S-100P, anti-EMA antibodies in different degrees, and negative with anti-desmin, anti-GFAP, anti-lysozyme antibodies. The positive reactions with anti-CEA, anti-actin, and anti-myoglobin are detected in a few individuals. Follow-up data show the recurrence rate and mortality of the SC are 73% and 18% respectively. The histogenesis of SC and differential diagnosis are also discussed in the paper.

Eosinophilic solid and cystic renal cell carcinoma with aggressive behavior:Two case reports

BACKGROUND Eosinophilic solid and cystic(ESC)renal cell carcinoma(RCC),a unique and emerging subtype of RCC,has an indolent nature;in some rare instances,it may exhibit metastatic potential.Current cases are inadequate to precisely predict the clinical outcome of ESC RCC and determine treatment choices.CASE SUMMARY Herein,we report two patients with ESC RCC.Patient 1 was a young woman with classical pathological characteristics.Patient 2 was a 52-year-old man with multifocal metastases,involving the pulmonary hilar and mediastinal lymph nodes,liver,brain,mesosternum,vertebra,rib,femur,and symphysis pubis.Awareness of ESC RCC,along with its characteristic architecture and immunophenotype,would contribute to making a definitive diagnosis,even on core biopsy samples.CONCLUSION The discovery of ESC RCC molecular signatures may provide new therapeutic strategies in the future.

Solid neuroendocrine breast carcinoma:mammographic and sonographic features in thirteen cases

This study aimed to determine and quantitate the mammographic and sonographic characteristics in 13 cases of solid neuroendocrine breast carcinoma(NEBC) and to analyze the association of radiological findings with the clinical and histopathologic findings.The clinical data and imaging findings of 13 female patients with histologically confirmed solid NEBC were reviewed.Imaging data were evaluated by two radiologists for a consensual diagnosis.All patients presented with one palpable mass;only 1 experienced occasional breast pain,and 5 complained of fluid discharge.In 7 patients,the masses were firm and mobile.Regional lymph node metastasis was noted in only 1 patient.For the 10 patients who underwent mammography,6 had a mass,1 had clustered small nodules with clustered punctuate microcalcifications,2 had asymmetric focal density,and 1 had solitary punctuate calcification.Most of the masses had irregular shape with indistinct or microlobulated margins.For the 9 patients who underwent ultrasonography(US),9 masses were depicted,all of which were hypoechoic,mostly with irregular shape and without acoustic phenomena.Different types of acoustic phenomena were also identified.One patient had developed distant metastases during follow-up.NEBC has a variety of presentations,but it is mostly observed on mammograms as a dense,irregular mass with indistinct or microlobulated margins.Sonographically,it typically presents as an irregular,heterogeneously hypoechoic mass with normal sound transmission.Histories of nipple discharge and calcification observed using imaging are not rare.

Role of Sulforaphane on Histone Deacetylase Activity in Solid Ehrlich Carcinoma

Histone acylation is one in every of the posttranslational modification that incorporates a role within the regulation of sequence expression. This study was aimed to ameliorate neoplasm cell model Solid Ehrlich malignant neoplastic disease with sulforaphane extracted from cabbage alone and together with immune suppressant drug (MTX) by study the activity of simple protein deacetylase accelerator (HDAC). In this study, sulforaphane was extracted from cabbage leaves and evaluated victimization GC-MS and ultraviolet illumination spectrophotometry. 60 white male rats were divided into six equal groups. Group I: management ordinarily. The remaining mice were subjected to Ehrlich neoplasm cells. Group II: Tumor-bearing group. Group III: immune suppressant drug “MTX” treated group. Group IV, V treated with SFN before and when Paul Ehrlich cells implantation group VI (Methotrexate and sulforaphane-treated group). This result showed that sulforaphane was extracted from cabbage (Brassica oleracea) in concentration of 833 μg/g leave. HDAC was attenuated when treatment with sulforaphane after treatment with methotrexate or sulforaphane alone. The desoxyribonucleic acid injury was attenuated in neoplasm tissue of tumor-bearing mice when treatment with immune suppressant drug and hyperbolic considerably in tumor tissue of tumor-bearing mice treated with sulforaphane before and after carcinogenesis and together with methotrexate treatment after carcinogenesis.

How to assess the efficacy or failure of targeted therapy:deciding when to stop sorafenib in hepatocellular carcinoma

Sorafenib is thus far the only systemic treatment for hepatocellular carcinoma(HCC) based on the results of two randomized controlled trials performed in Western and in Eastern countries, despite a poor response rate(from 2% to 3.3%) following conventional evaluation criteria. It is now recognized that the criteria(European Association of the Study of the Liver criteria, modified response evaluation criteria in solid tumors) based on contrast enhanced techniques(computed tomography scan, magnetic resonance imaging) aimed to assess the evolution of the viable part of the tumor(hypervascularized on arterial phase) are of major interest to determine the efficacy of sorafenib and of most antiangiogenic drugs in patients with HCC. The role of alphafetoprotein serum levels remains unclear. In 2016, in accordance with the SHARP and the Asia-Pacific trials, sorafenib must be stopped when tolerance is poor despite dose adaptation or in cases of radiological and symptomatic progression. This approach will be different in cases of available second-line therapy trials. Some recent data(in renal cell carcinoma) revealed that despite progression in patients who received sorafenib, this drug can still decrease tumor progression compared to drug cessation. Then, before deciding to continue sorafenib post-progression or shift to another drug, knowing other parameters of post-progression survival(Child-Pugh class, Barcelona Clinic Liver Cancer, alphafetoprotein, post-progression patterns in particular, the development of extrahepatic metastases and of portal vein thrombosis) will be of major importance.

Papillary carcinoma of breast: Minireview

The term "intracystic papillary ductal carcinoma in situ " constitutes only 0.5% to 1% of all breast cancers.It is usually seen in postmenopausal age group.Herein,we are presenting a minireview about this unusual breast malignancy usually difficult to diagnose on clinical grounds and highlighting modalities of diagnosis and management.

challenges of advanced hepatocellular carcinoma

Hepatocellular carcinoma(HCC) is an aggressive malignancy,resulting as the third cause of death by cancer each year. The management of patients with HCC is complex,as both the tumour stage and any underlying liver disease must be considered conjointly. Although surveillance by imaging,clinical and biochemical parameters is routinely performed,a lot of patients suffering from cirrhosis have an advanced stage HCC at the first diagnosis. Advanced stage HCC includes heterogeneous groups of patients with different clinical condition and radiological features and sorafenib is the only approved treatment according to Barcelona Clinic Liver Cancer. Since the introduction of sorafenib in clinical practice,several phase Ⅲ clinical trials have failed to demonstrate any superiority over sorafenib in the frontline setting. Locoregional therapies have also been tested as first line treatment,but their role in advanced HCC is still matter of debate. No single agent or combination therapies have been shown to impact outcomes after sorafenib failure. Therefore this review will focus on the range of experimental therapeutics for patients with advanced HCC and highlights the successes and failures of these treatments as well as areas for future development. Specifics such as dose limiting toxicity and safety profile in patients with liver dysfunction related to the underlying chronic liver disease should be considered when developing therapies in HCC. Finally,robust validated and reproducible surrogate end-points as well as predictive biomarkers should be defined in future randomized trials.

Acquired hemophilia A in solid cancer: Two case reports and review of the literature

Acquired hemophilia A(AHA) is a rare, hemorrhagic autoimmune disease, whose pathogenesis involves reduced coagulation factor Ⅷ(FⅧ) activity related to the appearance of inhibitors against FⅧ. Common etiological factors include autoimmune diseases, malignancy, and pregnancy. We report two cases of AHA in solid cancer. The first case is a 63-year-old man who developed peritoneal and intestinal bleeding after gastrectomy for gastric cancer. He was diagnosed with AHA, and was treated with prednisone, followed by cyclophosphamide. In the second case, a 68-year-old man developed a subcutaneous hemorrhage. He was diagnosed with AHA in hepatocellular carcinoma on CT imaging, and treated with rituximab alone. Hemostasis was achieved for both patients without bypassing agents as the amount of inhibitors was reduced and eradicated. However, both patients died within 1 year due to cancer progression. Successful treatment for AHA in solid cancer can be difficult because treatment of the underlying malignancy is also required.

Imaging response predictors following drug eluting beads chemoembolization in the neoadjuvant liver transplant treatment of hepatocellular carcinoma

BACKGROUND Drug-eluting bead transarterial chemoembolization(DEB-TACE)is an endovascular treatment to release chemotherapeutic agents within a target lesion,minimizing systemic exposure and adverse effects to chemotherapeutics.Therefore,identifying which patient characteristics may predict imaging response to DEB-TACE can improve treatment results while selecting the best candidates.Predictors of the response after DEB-TACE still have not been fully elucidated.This is the first prospective study performed with standardized DEBTACE technique that aim to identify predictors of radiological response,assessing patients clinical and laboratory characteristics,diagnostic imaging and intraprocedure data of the hepatocellular carcinoma treated in the neoadjuvant context for liver transplantation.AIM To identify pre-and intraoperative clinical and imaging predictors of the radiological response of drug-eluting bead transarterial chemoembolization(DEB-TACE)for the neoadjuvant treatment of hepatocellular carcinoma(HCC).METHODS This is prospective,cohort study,performed in a single transplant center,from 2011 to 2014.Consecutive patients with HCC considered for liver transplant who underwent DEB-TACE in the first session for downstaging or bridging purposes were recruited.Pre and post-chemoembolization imaging studies were performed by computed tomography or magnetic resonance.The radiological response of each individual HCC was evaluated by objective response using mRECIST and the percentage of necrosis.RESULTS Two hundred patients with 380 HCCs were examined.Analysis of the objective response(nodule-based analysis)demonstrated that HCC with pseudocapsules had a 2.01 times greater chance of being responders than those without pseudocapsules(P=0.01),and the addition of every 1mg of chemoembolic agent increased the chance of therapeutic response in 4%(P<0.001).Analysis of the percentage of necrosis through multiple linear regression revealed that the addition of each 1mg of the chemoembolic agent caused an average increase of 0.65%(P<0.001)in necrosis in the treated lesion,whereas the hepatocellular carcinoma with pseudocapsules presented 18.27%(P<0.001)increased necrosis compared to those without pseudocapsules.CONCLUSION The presence of a pseudocapsule and the addition of the amount of chemoembolic agent increases the chance of an objective response in hepatocellular carcinoma and increases the percentage of tumor necrosis following drug-eluting bead chemoembolization in the neoadjuvant treatment,prior to liver transplantation.

Assessment of clinical and radiological response to sorafenib in hepatocellular carcinoma patients

Sorafenib is an effective anti-angiogenic treatment forhepatocellular carcinoma(HCC). The assessment of tumor progression in patients treated with sorafenib is crucial to help identify potentially-resistant patients,avoiding unnecessary toxicities. Traditional methods to assess tumor progression are based on variations in tumor size and provide unreliable results in patients treated with sorafenib. New methods to assess tumor progression such as the modified Response Evaluation Criteria in Solid Tumors or European Association for the Study of Liver criteria are based on imaging to measure the vascularization and tumor volume(viable or necrotic). These however fail especially when the tumor response results in irregular development of necrotic tissue. Newer assessment techniques focus on the evaluation of tumor volume,density or perfusion. Perfusion computed tomography and Dynamic ContrastEnhanced-UltraS ound can measure the vascularization of HCC lesions and help predict tumor response to antiangiogenic therapies. Mean Transit Time is a possible predictive biomarker to measure tumor response. Volumetric techniques are reliable,reproducible and time-efficient and can help measure minimal changes in viable tumor or necrotic tissue,allowing the prompt identification of non-responders. Volume ratio may be a reproducible biomarker for tumor response. Larger trials are needed to confirm the use of these techniques in the prediction of response to sorafenib.

乳腺MRI对实性乳头状癌的诊断价值

目的:分析乳腺实性乳头状癌(solid papillary carcinoma,SPC)的磁共振成像(magnetic resonance imaging,MRI)特征,探究MRI对于SPC的诊断价值。方法:回顾并收集2017年1月—2021年12月上海交通大学医学院附属新华医院经手术后病理学检查证实为SPC且行术前MRI检查的患者57例(共61个SPC病灶)。57例患者中,行术前乳腺X线摄影及超声检查者分别为45例(48个SPC)和52例(55个SPC)。根据术前乳腺影像报告和数据系统(Breast Imaging Reporting and Data System,BI-RADS)分类结果,以BI-RADS≥4A类为可疑恶性,计算乳腺X线摄影、超声及MRI对SPC的检出率及诊断准确度。病灶形态分为非肿块强化(non-mass enhancement,NME)与肿块两组,两组大小比较采用Mann-Whitney U检验,伴随导管扩张的差异采用χ^(2)检验。结果:乳腺X线摄影、超声及MRI对SPC的检出率为分别为64.6%(31/48)、83.6%(46/55)和100.0%(61/61),诊断准确度分别为52.1%(25/48)、65.5%(36/55)和98.4%(60/61)。在MRI上,SPC表现为NME较肿块更多见(67.2%vs32.8%)。NME较肿块病灶更大[2.5(1.6,4.0)cmvs1.4(1.0,1.8)cm,P<0.001],伴随导管扩张的阳性率更高[82.9%(34/41)vs 25.0%(5/20),P<0.001]。结论:乳腺MRI对于SPC的检出率及诊断准确度均高于乳腺X线摄影和超声检查。在MRI上,SPC表现为NME较肿块更多见,前者病灶更大,更常伴随导管扩张。

Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up

Advanced stage hepatocellular carcinoma(HCC) is a category of disease defined by radiological, clinical and hepatic function parameters, comprehending a wide range of patients with different general conditions. The main therapeutic option is represented by sorafenibtreatment, a multi-kinase inhibitor with anti-proliferative and anti-angiogenic effect. Trans-arterial Radio Embolization also represents a promising new approach to intermediate/advanced HCC. Post-marketing clinical studies showed that only a portion of patients actually benefits from sorafenib treatment, and an even smaller percentage of patients treated shows partial/complete response on follow-up examinations, up against relevant costs and an incidence of drug related adverse effects. Although the treatment with sorafenib has shown a significant increase in mean overall survival in different studies, only a part of patients actually shows real benefits, while the incidence of drug related significant adverse effects and the economic costs are relatively high. Moreover, only a small percentage of patients also shows a response in terms of lesion dimensions reduction. Being able to properly differentiate patients who are responding to the therapy from non-responders as early as possible is then still difficult and could be a pivotal challenge for the future; in fact it could spare several patients a therapy often difficult to bear, directing them to other second line treatments(many of which are at the moment still under investigation). For this reason, some supplemental criteria to be added to the standard modified Response Evaluation Criteria in Solid Tumors evaluation are being searched for. In particular, finding some parameters(cellular density, perfusion grade and enhancement rate) able to predict the sensitivity of the lesions to anti-angiogenic agents could help in stratifying patients in terms of treatment responsiveness before the beginning of the therapy itself, or in the first weeks of sorafenib treatment. This would bring a strongly desirable help in clinical managements of these patients.

古草生机汤对H22荷瘤小鼠体内抑瘤及免疫调节作用的初步研究

目的:探究古草生机汤对H22荷瘤小鼠体内实体瘤的抑瘤功效和对机体的免疫调节作用机制。方法:本研究采用H22实体瘤动物模型,随机分为空白组、模型组、阳性药组、古草生机汤低、高剂量组,灌胃给药7 d,计算各组小鼠的体质量增长率、肿瘤抑制率、胸腺及脾指数,小鼠实体瘤病理切片苏木精-伊红(HE)染色观察瘤体组织和细胞形态,酶联免疫吸附试验法检测小鼠血清中γ干扰素(IFN-γ)、肿瘤坏死因子-α(TNF-α)、白细胞介素-2(IL-2)、Fas、Fas配体、天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)的含量,实时荧光定量PCR测量小鼠瘤组织中Bax和Bcl-2mRNA的相对表达量。结果:古草生机汤有促进H22荷瘤小鼠体质量增长、抑制体内实体瘤增长和促进肿瘤凋亡坏死的作用,可提高小鼠的胸腺指数同时降低脾脏指数,可显著提高小鼠血清中IFN-γ、TNF-α、IL-2的含量并降低Fas、Fas配体、AST、ALT的含量(均P<0.01),能够上调小鼠瘤组织中Bax mRNA的表达并下调Bcl-2mRNA的表达。结论:古草生机汤具有明显的体内抗肝肿瘤药效,在抑制肿瘤生长、促进肿瘤细胞凋亡、调节机体免疫方面有一定作用。

乳腺实性乳头状癌的超声表现及其病理学相关性研究

目的:探讨乳腺实性乳头状癌(solid papillary carcinoma of the breast,SPC)的灰阶超声、彩色多普勒超声及超声弹性成像表现,并探讨SPC的超声表现与其病理学检查结果的相关性。方法:分析71例经术后病理学检查证实的SPC患者的临床资料,共包括75个SPC病灶的灰阶超声、彩色多普勒超声表现和35个SPC病灶的超声弹性成像表现。比较不同病理学亚型SPC的超声表现及与病理学检查结果的相关性。结果:SPC的超声表现大多为单发的低回声实性肿块,呈水平生长,形态不规则,边缘不光整,后方回声增强或不变,可伴有导管扩张及钙化,Adler血流分级Ⅱ~Ⅲ级,阻力指数(resistance index,RI)为0.62~0.84。几乎不伴有腋窝淋巴结转移。75个SPC病灶病理学分子分型均为Luminal A型。Ki-67增殖指数在42个原位SPC病灶中均<20%,在15个浸润性SPC中为20%~60%,两者差异有统计学意义(P=0.000)。结论:SPC超声表现具有一定特征性,结合灰阶、彩色多普勒超声及超声弹性成像可提高其诊断准确度,但超声无法鉴别原位SPC及浸润性SPC,Ki-67增殖指数与SPC是否浸润有关。

靶向GPC3的CAR-T细胞治疗肝癌研究进展

嵌合抗原受体T细胞(CAR-T)是治疗肿瘤的新型免疫疗法,磷脂酰肌醇蛋白聚糖3(GPC3)在肝癌(HCC)组织中高表达,是治疗HCC的理想靶标,靶向GPC3的CAT-T细胞治疗HCC效果显著,被认为是最具潜力的免疫疗法之一。本文对靶向GPC3 CAR-T细胞治疗HCC的最新研究进展进行综述。

嗜酸性实性和囊性肾细胞癌3例并文献复习

嗜酸性实性和囊性肾细胞癌(eosinophilic solid and cystic renal cell carcinoma,ESC RCC)是一种发生于女性的肾细胞癌的新亚型。绝大多数ESC RCC是散发性的,少数伴结节性硬化症。本研究回顾济宁医学院附属医院3例ESC RCC患者的临床资料,并分析其组织细胞形态及免疫表型特点。3例患者组织学均表现为腺泡状和巢状分布的嗜酸性大细胞并混有微囊区域,囊壁被覆细胞呈“鞋钉样”排列,病理学诊断为ESC RCC。患者1行肾根治术,随访26个月,无复发或远处转移;患者2、3行肾楔形切除术,随访分别随访14个月、4个月,无复发或远处转移。ESC RCC预后一般良好,但有极少数患者预后不良。本研究3例患者均不伴结节性硬化症,术后预后良好,无局部浸润和转移倾向,随访至今,均无复发迹象。

New approaches for precise response evaluation in hepatocellular carcinoma

With the increasing clinical use of cytostatic and novel biologic targeted agents,conventional morphologic tumor burden assessments,including World Health Organization criteria and Response Evaluation Criteria in Solid Tumors,are confronting limitations because of their difficulties in distinguishing viable tumor from necrotic or fibrotic tissue.Therefore,the investigation for reliable quantitative biomarkers of therapeutic response such as metabolic imaging or functional imaging has been desired.In this review,we will discuss the conventional and new approaches to assess tumor burden.Since targeted therapy or locoregional therapies can induce biological changes much earlier than morphological changes,these functional tumor burden analyses are very promising.However,some of them have not gone thorough all steps for standardization and validation.Nevertheless,these new techniques and criteria will play an important role in the cancer management,and provide each patient more tailored therapy.

3.0T MRI对无瘢痕的肾嗜酸细胞腺瘤与实性肾透明细胞癌的鉴别诊断价值

目的探讨3.0T磁共振表观扩散系数ADC值及动态增强特征在无瘢痕的(肿块质地均匀,中心无星芒状瘢痕)肾嗜酸细胞腺瘤(renal oncocytoma,RO)与实性肾透明细胞癌(clear cell renal cell carcinoma,CCRCC)鉴别诊断的价值。方法选取经手术病理证实的42例无瘢痕的RO和实性CCRCC,其中15例为无瘢痕的RO(无瘢痕RO组)和27例实性CCRCC(CCRCC组)患者的资料。所有患者术前均行MRI扩散加权成像及增强扫描。对ADC值及增强扫描各期强化程度值进行定量测量,采用多因素Logistic回归分析确定ADC比值及增强皮质-排泄期信号强度比值鉴别两种肿瘤的独立影响因素,以病理结果为金标准,绘制受试者工作特征曲线(ROC),计算曲线下面积(AUC)并做比较。结果RO患者的ADC比值高于CCRCC患者,差异有统计学意义(P<0.05),ADC测量的ROC AUC、灵敏度和特异度分别为0.727、75.6%和72.1%;RO患者的皮质-排泄期信号强度比值低于CCRCC患者,差异有统计学意义(P<0.05),对应比值测量的ROC AUC、灵敏度和特异度分别为0.846、91.2%和89.6%。ADC值联合皮质-排泄期信号强度比值的ROC分析发现,鉴别两者的AUC、敏感度及特异度分别为0.895、93.6%、91.3%。结论磁共振表观扩散系数ADC比值及皮质-排泄期信号强度比值均有助于鉴别无瘢痕的RO和CCRCC,两种参数结合能更好的鉴别这两种肿瘤。

囊实性甲状腺癌与结节性甲状腺肿囊性变的超声鉴别诊断

目的探讨二维及彩色多普勒超声在囊实性甲状腺癌与结节性甲状腺肿囊性变鉴别诊断中的价值。方法回顾性分析36例囊实性甲状腺癌与72例结节性甲状腺肿囊性变的超声图像特点。结果囊实性甲状腺癌实性部分多分布于肿物一侧(偏心分布)或包绕囊性部分,多呈低回声或极低回声,多伴砂砾样钙化,血流信号多为中央型。结节性甲状腺肿实性部分多与囊性部分交叉分布,多呈低回声、等回声,多有粗大钙化,多为混合型血流信号。结论二维及彩色多普勒超声对囊实性甲状腺癌及结节性甲状腺肿囊性变的鉴别诊断有一定的帮助。

乳腺实性乳头状癌临床病理分析

目的：探讨乳腺实性乳头状癌（ solid papillary carcinoma, SPC）的临床病理学特点、组织学特征及预后。方法对9例SPC进行组织形态学观察,行AB-PAS染色和免疫组化MaxVision法染色,对其临床资料进行跟踪随访、分析并复习相关文献。结果9例SPC患者年龄32～83岁,平均69．2岁,其中以乳头溢液发病3例；9例核级别为低～中级别,7例细胞内和细胞外伴黏液分泌,2例伴钙化,3例伴粉刺样坏死。9例ER、PR均阳性且阳性率较高（均〉70%）,HER-2均阴性。9例SPC中神经内分泌标志物Syn呈弥漫阳性（8例）、灶阳性（1例）；CgA有4例呈弥漫阳性,1例部分阳性,4例呈阴性；6例有部分区域肌上皮标志物表达缺失,3例肌上皮标志物连续表达；Ki-67增殖指数为3%～20%。9例SPC中有1例伴小灶性浸润性导管癌（ invasive ductal carcinoma, IDC）（最大径2 mm）,其余8例均不伴其它类型乳腺癌,前哨和（或）腋窝/锁骨下淋巴结均未见癌转移。9例中有8例进行乳腺癌保乳根治术,1例为局部肿物切除过程中偶然发现微小病灶,未行根治术；9例中有1例因伴有IDC,行4周期TC方案化疗,化疗耐受可,目前处于化疗后恢复期；其余8例术后口服内分泌药物治疗,临床密切随访观察,随访时间3～61个月（平均19.6个月）,均未发现复发。结论9例SPC均表现为核级别较低、常伴细胞内外黏液分泌、神经内分泌标志物阳性、淋巴结转移率低等特点,随访未发现复发,提示SPC临床预后较好。